Neuroone Medical Technologies (NMTC) Net Income towards Common Stockholders (2010 - 2026)

Neuroone Medical Technologies (NMTC) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$2.4 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 4.91% year-over-year to -$2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.9 million (down 5.1% YoY) and the FY2025 annual result came in at -$3.6 million, up 70.73% from the prior year.
• Net Income towards Common Stockholders retreated to -$2.4 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $1.8 million in Q4 2024 to a low of -$3.5 million in Q1 2023.
• A 5-year average of -$2.3 million and a median of -$2.8 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders surged 153.37% — and 2025, when it sank 180.54%.
• Tracing NMTC's Net Income towards Common Stockholders over 5 years: stood at -$1.7 million in 2022, then slumped by 93.04% to -$3.3 million in 2023, then surged by 153.37% to $1.8 million in 2024, then sank by 180.54% to -$1.4 million in 2025, then slumped by 65.66% to -$2.4 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$2.4 million (Q1 2026), -$1.4 million (Q4 2025), and -$1.6 million (Q3 2025), per Business Quant data.